Xenon Pharmaceuticals (NASDAQ:XENE) Earns Overweight Rating from Analysts at Wells Fargo & Company
Wells Fargo & Company began coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research report report published on Wednesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $48.00 target price on the biopharmaceutical company’s stock. A number of other equities analysts have also recently weighed in on XENE. […]
More Stories
Musk Says X’s New Algorithm Will Be Open Source in 6 Days
By Jacob Burg Elon Musk said on Jan. 10 that his X social media platform would open its new algorithm...
Trump Urges Cuba to Strike Deal With US After Oil, Money Cut Off From Venezuela
By Jacob Burg U.S. President Donald Trump on Jan. 11 told Cuba that it should forge a deal with the...
Wall Street Review: Stocks Close Out Strong Week on Labor Market Clarity
By Panos Mourdoukoutas Equities resumed their rally this week as investors gained a clearer view of the labor market following...
Protests Spread in Iran as Regime Vows to Retaliate Against Any US Attack
By Jacob Burg The Iranian regime threatened on Jan. 11 to strike Israeli and U.S. military bases if Washington attacks...
ICE Agent Involved in Shooting Is Getting Death Threats, Border Czar Says
By Jack Phillips White House border czar Tom Homan defended Immigration and Customs Enforcement (ICE) amid protests against the agency...
Overhauling Air Traffic Control Involves 5,000 Locations and 600 Radar Systems—What to Know
By Jacob Burg The federal government is embarking on what Transportation Secretary Sean Duffy has called “the most important infrastructure...